Q32 Bio Inc.

NASDAQ:QTTB

Biotechnology

Healthcare
$8.53 -1.70%

-$0.22 today

Market cap
$255.25M
Beta
-0.23
P/E (TTM)
5.4
EPS (TTM)
$2.36
52W Low $1.35High $14.85

Volume 0.26M

Average 0.74M

QTTB Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Q32 Bio Inc.NASDAQ: QTTB

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit remains negative

Q1 FY2026 gross profit was -$90K, compared with -$119K a year earlier. Trailing-twelve-month gross profit was $53.38M. Over 3 fiscal years it compounded at +100.2% a year.

Context

  • Gross profit amounted to 99.3% of revenue in FY2025.
  • Gross profit increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near -$90K or moves back toward the trailing-twelve-month quarterly average of $13.34M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$90K-100.2% QoQ
Last fiscal yearDec 2025
$53.35M+11054.0% YoY
LTMMar 2026
$53.38M+14926.4% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+24.4%——
1 year+11054.0%——
3-year CAGR+100.2%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
53.35M USD
Year-over-year change
+11054.0%
4-year CAGR
+21.6%

Gross Profit vs competitors

How QTTB compares with its peers on the latest reported figures

  • QTTB's LTM Mar 2026 gross profit of $53.38M is the highest of the 5 companies compared; the peer median is -$609K.
  • Its year-over-year change of +14926.4% is the highest of 4, against a peer median of +77.4%.
  • Gross profit amounts to 99.3% of revenue for QTTB, versus a peer median of 89.5%.
QTTB Competitors Peer median
Gross Profit for QTTB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
QTTBQ32 Bio Inc.LTM Mar 2026$53.38M +14926.4%+100.2%99.3%
VRCAVerrica Pharmaceuticals Inc.LTM Mar 2026$33.27M +545.5%+57.0%89.5%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$0 ———
BOLDBoundless Bio, Inc.LTM Mar 2026-$1.22M -359.6%——
SABSSAB Biotherapeutics, Inc.LTM Jun 2026-$2.28M +77.4%——
Peer median (excluding QTTB) -$609K+77.4%+57.0%89.5%

Competitors are the stored peer set for QTTB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue33.97M6.65M(6.65M)053.74M
Cost of Revenue9.54M2.6M499K487K391K
Gross Profit24.43M6.65M(6.65M)(487K)53.35M
Gross Margin71.9%100.0%100.0%—99.3%
Research & Development93.09M35.81M31.73M48.14M19.16M
Selling, General & Admin27.29M10.06M9.88M17.47M17.68M
Operating Expenses120.38M45.88M41.6M65.61M36.44M
Depreciation & Amortization9.54M370K499K487K391K
EBITDA(86.22M)(38.86M)(47.76M)(45.3M)17.29M
EBITDA Margin-253.8%-584.2%718.0%—32.2%
Operating Income(95.95M)(39.23M)(48.26M)(66.1M)16.9M
Operating Margin-282.4%-589.8%725.5%—31.5%
Interest Income185K3.23M03.9M2.2M
Interest Expense000300K1.1M
Other Income / Expenses185K(3.52M)(5.17M)18.39M12.92M
Income Before Tax(95.76M)(42.75M)(53.43M)(47.71M)29.82M
Pre-Tax Margin-281.9%-642.7%803.3%—55.5%
Income Tax Expense062K318K21K0
Net Income(95.76M)(42.81M)(53.74M)(47.73M)29.82M
Net Margin-281.9%-643.6%808.0%—55.5%
EPS (Basic)(31.18)(13.42)(16.70)(5.12)2.42
EPS (Diluted)(31.18)(13.42)(16.70)(6.58)2.42
Weighted Avg Shares3.07M3.19M3.22M12.2M12.3M
Weighted Avg Shares (Diluted)3.07M3.19M3.22M12.2M12.31M

Q32 Bio Inc.

NASDAQ:QTTB

Intrinsic Alpha fair value

Locked

Current Price

$8.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.